HHS delays rule that could void thousands of regulations

HHS on March 18 postponed a final rule that would require the agency to review its existing regulations within several years and to invalidate those that aren’t reviewed. 

Advertisement

HHS postponed the final rule by one year, pending judicial review, according to the American Hospital Association. The move comes after a coalition of health groups and others sued HHS March 9 over the rule. 

The lawsuit, pending in U.S. District Court of the Northern District of California, alleges that thousands of HHS regulations could disappear because of the Securing Updated and Necessary Statutory Evaluations Timely, or SUNSET, rule, which was finalized the day before President Joe Biden’s inauguration. 

“The rule does not even specify which of the department’s 18,000 existing regulations are exempted under the limited exceptions. In other words, the outgoing administration planted a ticking time bomb set to go off in five years unless HHS, beginning right now, devotes an enormous amount of resources to an unprecedented and infeasible task,” the complaint states. 

The AHA has urged HHS to withdraw the rule, arguing it doesn’t provide an adequate mechanism for obtaining public input on the substance of the regulations reviewed. 

More articles on legal and regulatory issues:
Investigation launched after Indiana nurse unhooked oxygen from COVID-19 patient
Ex-New Jersey hospital employee charged with stealing $8.2M worth of medication
Texas pharma CEO charged in $134M scheme

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.